Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pirfenidone
Drug ID BADD_D01783
Description Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
Indications and Usage For the treatment of idiopathic pulmonary fibrosis (IPF).
Marketing Status approved; investigational
ATC Code L04AX05
DrugBank ID DB04951
KEGG ID D01583
MeSH ID C093844
PubChem ID 40632
TTD Drug ID D02WCI
NDC Product Code 0480-3610; 60862-005; 69766-030; 76072-1006; 42385-924; 69539-120; 42385-923; 42385-925; 42571-336; 69097-940; 72205-182; 0781-8085; 0480-3611; 65372-1197; 82920-705; 16729-468; 46708-479; 69238-1640; 62332-480; 0781-2158; 62207-004; 31722-872; 50228-442; 69539-119; 57297-140; 73309-052; 46708-480; 69097-988; 69238-1641; 42571-329; 46016-5312; 31722-873; 72205-181; 76282-716; 0781-8086; 53104-7712; 69037-0013; 60219-1640; 60219-1641; 47621-311; 59285-013; 59651-199; 50228-443; 50242-121; 60219-1642; 62332-479; 46016-5310; 16729-467; 42385-926; 42571-335; 50228-441; 50242-122; 69097-987; 76282-715; 76282-717; 11014-0214; 46438-0648; 62512-0070; 50242-123
UNII D7NLD2JX7U
Synonyms pirfenidone | 5-methyl-1-phenyl-2-(1H)-pyridone | Esbriet | deupirfenidone | 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one | Deskar
Chemical Information
Molecular Formula C12H11NO
CAS Registry Number 53179-13-8
SMILES CC1=CN(C(=O)C=C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chapped lips07.05.01.0040.000530%Not Available
Sudden cardiac death08.04.01.008; 02.03.04.0160.000241%Not Available
General physical health deterioration08.01.03.0180.006124%Not Available
Muscle fatigue15.05.03.006--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Cardiac death08.04.01.007; 02.03.04.0150.000241%Not Available
Intervertebral disc protrusion15.10.01.0040.000362%Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.0030.000241%Not Available
Penile discharge21.12.01.0050.000530%Not Available
Deep vein thrombosis24.01.02.003--Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000603%Not Available
Dyschezia07.02.03.0050.000241%Not Available
Photodermatosis23.03.09.0040.000530%Not Available
Exercise tolerance decreased08.01.03.0360.000362%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000362%Not Available
Metastases to peritoneum07.21.03.003; 16.22.02.0080.000241%Not Available
Respiratory tract congestion22.02.07.0030.000241%Not Available
Upper respiratory tract congestion22.12.03.0330.000530%Not Available
Epigastric discomfort07.01.02.0040.001061%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Secretion discharge08.01.03.0190.001471%Not Available
Cerebral haematoma24.07.04.006; 17.08.01.0140.000241%Not Available
Skin burning sensation17.02.06.009; 23.03.03.021--Not Available
Cerebral disorder17.02.10.0170.000241%Not Available
Varices oesophageal24.10.02.004; 07.15.05.001; 09.01.06.0090.000241%Not Available
Pulmonary mass22.02.07.0040.000723%Not Available
Cutaneous lupus erythematosus23.03.02.008; 15.06.02.007; 10.04.03.0070.000241%Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000723%Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.000241%Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.003665%Not Available
The 9th Page    First    Pre   9 10 11 12    Next   Last    Total 12 Pages